36th Annual
J.P. Morgan Healthcare Conference

MICROBIO GROUP

A Taiwanese Leading Biotech Since 1997

MICROBIO Group Profile

- ***1997*** Established with ***4*** listed in Taiwan
- ***700*** million USD Investment in R&D
- ***12*** New Drugs Pipeline
- ***4*** R&D Centers
- ***2*** PIC/s GMP Standard Manufacturing Plants in Taiwan
- ***1*** GMP Manufacturing Plant in China
- ***80*** In-House Scientists + ***5*** Research institutions

Product Pipeline

Phase 1	Phase 2	Phase 3	Approved
OB318 HCC	**FB317** Anti-IgE	**FB825** Anti-CcmX	**ON101** Diabetic Foot Ulcer	**MS-20** Oncology
MB-110 HCV	**SNP630** NASH		**MB-6** Colon Cancer	**Herbiron** Anemia
FB704A Anti-IL-6	**SNP810** Analgesic and antipyretic			

2 Approved Drugs and 8 Programs on Clinical Stage

MICROBIO GROUP
www.microbiogp.com

ON101 (DFU Cream)

Outstanding Phase III Interim Result

Wound Healing Rate > 60%

DFU-Unmet Medical Need

MICROBIO GROUP

DM patients worldwide 425 million



25% has DFU	>50% DFU patients Infected	20% DFI patients amputated

DFU mortality in 5 Years 50 %

DFU – A Major Economic Impact

MICROBIO GROUP

2014 USA

- **DFU imposes substantial burden on public and private payers, ranging from $9-13 billion in addition to diabetes treatment costs.** (Diabetes Care 2014;37: 651-658)

2012 Europe

- **The estimated costs associated with treatment of DFU are EUR 10 billion per year in Europe.** (Int Wound J 2013; 10: 555-561)

2018 China

- **There are estimated 7 million DFU patients in China costing $21 billion in medical expenditure from hospital admission per capita is $3000.**

ON101 Phase III Interim Result

MICROBIO GROUP

- Overall Group





Difference = 30.5% (p<0.001)

- Plantar Ulcers Group





Difference = 39.5% (p=0.002)

- Large Wound Size (> 5 cm^2) Group





Difference = 51.2% (p=0.002)

60% Complete Healing in 16 Weeks

ON101 Development Plan



Looking for Strategic Partners

MICROBIO GROUP
www.microbiogp.com

MS20 (Commensal bacterial metabolites)

New Indication Development

on Human Gut Ecosystem and PD-1 booster

Limited Response Rate of Immune Checkpoint Inhibitors

MICROBIO GROUP

ORR			
	Opdivo	Keytruda	Yervoy
Melanoma	25-35 %	24-32 %	11 %
Lung cancer	41 %	20-26 %	-
Kidney cancer	11-25 %	-	-
Off-label use			
Prostate cancer	-	-	26 %
Triple-negative breast cancer	-	16 %	-
Ovarian cancer	-	12 %	-



Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Science. 2015, 350(6264):1084-1089

MS-20 Human Gut Microbiota Ecosystem

MICROBIO GROUP

Bifidobacterium spp. (beneficial bacteria)

Clostridium perfringens (gut pathogen)



* $p<0.05$ compared with baseline

MS-20 Turn Cold to Hot tumors

MICROBIO GROUP

Boosting tumor infiltrating CD4⁺/CD8⁺ T cells



Vehicle



15% MS-20



15% MS-20 + anti-PD-1

Blue: Tumor cells ; Green: Dendritic cell

Yellow: CD4⁺ T cells ; Red: CD8⁺ T cells

MS-20 Enhance Anti-tumor Immunity

Combination Therapy of MS-20 & Anti-PD-1





Improved Survival Rate and Reduced Tumor Size

MS-20 Opportunity

1. Market Product Modulates Human Gut Microbiome
2. Enhancement of Immune Checkpoint Blockade

Looking for Strategic Partners

MICROBIO GROUP
www.microbiogp.com

FB825 (Anti-CεmX)

First-in-Patient Data

on Moderate-to-Severe Atopic Dermatitis

FB825 Clinical Site and PI

- **Top Ranked Medical Center in Taiwan**

  National Taiwan University Hospital

- **Chia-Yu Chu MD, PhD**
  - **CEO, National Taiwan University Hospital International Medical Service Center**
  - **Director, Taiwanese Dermatological Association**
  - **Editor-in Chief, Dermatologica Sinica**
  - **Chairman, 6th Euro-Asian Association of Dermatovenerologists Congress**
  - **Conducted global trials for Atopic Dermatitis including Anti-IL4R, Anti-IL13, JAK inhibitors, etc.**

FB825 Clinical Design (Exploratory Study)

MICROBIO GROUP



Screening (4 weeks) Emulsion standardization (1 week)	5mg/kg IV Q12W 2 doses (n=12)

- Eczema Area and Severity Index (EASI) score ≧14
- Investigator's Global Assessment (IGA) score ≧ 3
- ≧10 % body surface area (BSA) of Atopic Dermatitis involvement

12 Weeks per Dose
on Moderate-to-Severe Atopic Dermatitis

FB825 Compare with Dupilumab

	EASI Score Change from Baseline							Dose Interval
	W1	W2	W4	W8	W12	W13	W16	
FB825	-40%	-45%	-53%	-70%				12W per dose
Dupilumab*	-15%	-35%	-55%	-66%	-70%	NA	-70%	2W per dose

*Phase III Trial Results, Dupilumab is currently the only approved biologics for atopic dermatitis.

260% Improvement over Dupilumab at Week 1
One dose/8w of FB825 is equal to 4 doses/8w of Dupilumab

FB825 Significant Reduction

MICROBIO GROUP





1 dose / 8 Weeks

70% Reduction in EASI
42% Reduction in SCORAD

FB825

Breakthrough Findings in Atopic Dermatitis

- **Earlier Onset**
  - **EASI score reduced by 40% in the first week after dosing**
- **Longer Effect**
  - **Be effective up to 2 months by single dose**
  - **1 dose of FB825 are comparable to 4 doses of dupilumab** (based on current data)
- **Minor Side Effect**
  - **No local reaction observed**

FB825

MICROBIO GROUP

Looking for Strategic Partnership

- In-licensing
- Co-development

MICROBIO GROUP

Thank You Very Much